When Tracy Dixon-Salazar’s daughter Savannah began experiencing severe, unexplained seizures in the mid-1990s, the medical community offered little in the way of hope or answers. Diagnosed with Lennox-Gastaut Syndrome, a rare and debilitating form of pediatric epilepsy, Savannah’s condition resisted all standard medical interventions. Facing the prospect of her daughter’s life being cut short, Dixon-Salazar took a path that would change the trajectory of their lives and the field of neurogenetics.
Starting as a parent with no formal medical training, Dixon-Salazar returned to school, eventually earning a PhD and completing a postdoctoral fellowship in neurogenetics. She dedicated herself to understanding the biological roots of epilepsy, balancing 80-hour work weeks in the laboratory with the intensive care her daughter required at home. Her research into genomic sequencing allowed her to analyze Savannah’s unique genetic makeup with a precision that had previously eluded the medical establishment.
After analyzing hundreds of variants, Dixon-Salazar identified a specific mutation that caused excessive calcium to reach Savannah’s neurons. She proposed an unconventional treatment using a calcium channel blocker typically reserved for heart conditions. This discovery, which she refers to as her twenty-seventh attempt at treatment, successfully reduced Savannah’s seizure frequency by 95 percent. This breakthrough provided Savannah with eleven years of improved quality of life that her doctors had once deemed impossible.
Although Savannah passed away last year at age 31, her mother’s work continues through the LGS Foundation. As the organization’s President and CEO, Dixon-Salazar now leads research initiatives and patient advocacy programs, ensuring other families have access to the same genetic screening and data-driven care that saved her daughter. The landscape of epilepsy research has changed significantly since she began, growing from a handful of known genetic links to over 1,500 today.
Her story serves as a record of what occurs when clinical research is driven by direct, personal necessity. By bridging the gap between raw data and patient outcomes, Dixon-Salazar has turned a personal hardship into a foundation for ongoing medical progress in pediatric neurology.